scholarly journals High incidence of stroke and mortality in pediatric critical care patients with COVID-19 in Peru

Author(s):  
Alvaro Coronado Munoz ◽  
Jaime Tasayco ◽  
Willy Morales ◽  
Luis Moreno ◽  
David Zorrilla ◽  
...  

Abstract Introduction: Pediatric critical care patients with COVID-19 treated in Peru have higher mortality than those previously reported from other countries. Pediatric providers have reported a high number of patients without comorbidities presenting with hemorrhagic strokes associated with COVID-19. We present a study analyzing the factors associated with mortality in this setting.Methods: Prospective case-control study that included patients < 17 years old admitted to a pediatric critical care unit with a positive test confirming COVID-19. The primary outcome was mortality, and secondary outcomes were laboratory results and length of stay. Fisher’s exact test and the Mann-Whitney U test were used for the analysis.Results: Forty-seven patients were admitted to critical care. The mortality of our study is 21.3%. The mortality of patients with neurological presentation was 45.5%, which was significantly higher than the mortality of acute COVID-19 (26.7%) and MIS-C (4.8%), p 0.18. Other risk factors for mortality in our cohort were strokes and comorbidities. Only one patient presenting with hemorrhagic stroke had an undiagnosed comorbidity.Conclusion: Cerebrovascular events associated with COVID-19 in pediatric patients, including infants, must be recognized as one of the more severe presentations of this infection in pediatric patients.

Author(s):  
Alvaro Coronado Munoz ◽  
Jaime Tasayco ◽  
Willy Morales ◽  
Luis Moreno ◽  
David Zorrilla ◽  
...  

2006 ◽  
Vol 102 (4) ◽  
pp. 1045-1050 ◽  
Author(s):  
Richard J. Berens ◽  
Michael T. Meyer ◽  
Theresa A. Mikhailov ◽  
Krista D. Colpaert ◽  
Michelle L. Czarnecki ◽  
...  

2018 ◽  
Vol 46 (1) ◽  
pp. 656-656 ◽  
Author(s):  
Jodi Mullen ◽  
Joshua Campbell ◽  
Melissa Reynolds

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 9044-9044
Author(s):  
C. E. Herzog ◽  
W. Huh ◽  
N. Jaffe ◽  
J. Durand

9044 Background: Despite the effectiveness of doxorubicin (D) in sarcomas, its use is limited by cardiotoxicity. Both delivery by continuous infusion (CI) and use of the cardioprotectant dexrazoxane (Z) have been used to reduce cardiotoxicity. Since 1998 patients with Ewing’s sarcoma seen at MDACC have been treated with a total of 540 mg/m2 D given with Z (ZD). During this period patients with osteosarcoma have been treated with 360–540 mg/m2 D given as a 48-hour infusion (CID). Methods: To compare the cardiotoxicity of ZD versus CID, we did a retrospective review of patients seen on the pediatric service at MDACC since 1998. Patients included needed to have had 1) planned therapy of at least 360 mg/m2 D, given either as ZD or CID; 2) measurement of ejection fraction (EF) prior to any D; and 3) routine monitoring of cardiotoxicity with EF. Patients were recorded as having cardiotoxicity for any EF<50% or clinical symptoms. Groups were compared by 2-sided t-test and Fisher’s Exact test. Results: A total of 64 patients were treated with ZD or DCI, 52 of which are evaluable. Comparison of ZD to CID showed no significant difference in age or male:female ratio. Total D dose was higher in ZD. Cardiotoxicity was higher in DCI as determined by number of patients with cardiotoxicity and EF on worst Echo. Conclusions: Despite the higher total dose of D, patients treated with ZD had less cardiotoxicity. Whether this is due to giving a cardioprotectant or other factors, such as, higher degree of electrolyte abnormalities or greater degree of anemia in patients treated with CID needs to be investigated. [Table: see text] No significant financial relationships to disclose.


Sign in / Sign up

Export Citation Format

Share Document